GILDPDUFA
Bictegravir/Lenacapavir (BIC/LEN) (Antiretroviral Combination)
Human Immunodeficiency Virus
Approval decisionFDA regulatory calendar
Track FDA action dates and advisory committee meetings by month. Each event links to its company, drug, indication and source-backed research record.
Use the monthly FDA calendar to review PDUFA target dates and advisory committee meetings, then open each event for drug, company, indication and source context.